The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June. The index is now on the verge of hitting a record high, which is interesting since just two months ago, it was on the brink of a bear market.
The S&P 500 came to its lowest point of the year on April 8, down 18.9% from its February record high, following President Trump’s “Liberation Day” tariffs on April 2. However, in April, after the President retracted his substantial “reciprocal” tariffs, it experienced a significant rally. The recovery then picked up speed, and the index rose 6.15% throughout May.
According to Ross Mayfield, an investment strategist at Baird, as the market has rebounded, momentum surrounding US tech and AI has started to pick up pace. Stocks from these industries are starting to regain their “leadership” in US markets, which is helping propel the key indexes higher. Speaking on this, Mayfield added the following:
“Does it become a bubble at some point? I think it’s possible, but I don’t think we’re there yet. And in the meantime, getting leadership from these big tech names is huge for a US market that’s hyper-concentrated in that area.”
Other factors that could affect market sentiment and investor attitude include geopolitics and second-quarter earnings reports starting in mid-July. Christopher Brigati of SWBC, however, thinks investors should refrain from acting hastily based on the market’s immediate response.
“The main message for investors is to stay invested and avoid reacting sharply to any news or market reaction that may have a short-term negative impact upon equity prices. It is nearly impossible to attempt to time the market, therefore maintaining a disciplined and long-term investing approach serves investors well.”
Our Methodology
To compile our list for the 30 stocks expected to beat the market, we first identified US-listed companies with solid financials and growth prospects. From this pool, we narrowed downs stocks that analysts predict would surpass the S&P 500 by at least 20%. Lastly, these stocks were ranked based on the number of hedge funds holding positions in them as of the end of Q1 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
30. VinFast Auto Ltd. (NASDAQ:VFS)
Analyst Upside: 69.48%
Number of Hedge Fund Holders: 8
VinFast Auto Ltd. (NASDAQ:VFS) ranks among our list of the 30 stocks expected to beat the market by 20 percentage points this year. Cantor Fitzgerald reiterated its $6 price target and Overweight rating for VinFast Auto Ltd. (NASDAQ:VFS) on June 10 in response to the company’s 2025 first-quarter financial results.
VinFast Auto Ltd. (NASDAQ:VFS) reported a substantial increase in revenue from the previous year, with first-quarter revenues reaching $656.5 million. This figure was considerably greater than the $271.9 million recorded in the same quarter of the prior year and exceeded Cantor Fitzgerald’s projections of $447.5 million.
The company delivered 36,330 vehicles throughout the quarter, representing a significant increase from the 9,176 vehicles delivered during the first quarter of 2024. The VF3 and VF5 models from VinFast Auto Ltd. (NASDAQ:VFS) were considered the primary catalyst for this rise.
Despite falling short of Cantor Fitzgerald’s projections of negative 30.2%, the company’s reported gross margins for the quarter were about negative 35.2%, making it an improvement over the negative 79% gross margin in the fourth quarter of 2024.
VinFast Auto Ltd. (NASDAQ:VFS) is a Vietnamese multinational automotive company founded by Vingroup, one of Vietnam’s largest private corporations.
29. ImmunityBio, Inc. (NASDAQ:IBRX)
Analyst Upside: 122.89%
Number of Hedge Fund Holders: 10
ImmunityBio, Inc. (NASDAQ:IBRX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $8, H.C. Wainwright analysts reiterated their Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX) on June 4. The decision comes after the company’s recent regulatory triumphs, which include the FDA’s Expanded Access authorization for its Cancer BioShield platform this month and the RMAT designation it received in February.
The Cancer BioShield platform, which addresses immune collapse in malignancies that prove difficult to treat, is anchored by ANKTIVA and PD-L1 t-haNK CAR-NK cells. In that regard, ImmunityBio, Inc. (NASDAQ:IBRX) provided evidence at the ASCO 2025 conference that ANKTIVA (N-803), an IL-15 superagonist, is the first authorized lymphocyte-stimulating drug that can reverse treatment-induced lymphopenia.
In a Phase 2 QUILT-88 study, ANKTIVA, SBRT, PD-L1 t-haNK cells, and low-dose chemotherapy together demonstrated an increase in survival associated with immune restoration in 86 patients with advanced pancreatic cancer. Given that more than 77% of trial participants saw immune recovery, the analysts underlined the importance of these results and pointed out that ANKTIVA is a novel strategy for treating immune system collapse.
ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company committed to developing novel cancer treatments by using cellular immunotherapy, which targets cancer cells by utilizing the body’s immune system.
28. Summit Therapeutics Inc. (NASDAQ:SMMT)
Analyst Upside: 66.17%
Number of Hedge Fund Holders: 20
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Analysts at H.C. Wainwright reaffirmed their Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on June 2, citing a $44 price target. The analysts emphasized how Summit Therapeutics’ medication ivonescimab holds the potential to emerge as an elite checkpoint inhibitor for the treatment of solid cancers.
In spite of the overall survival hazard ratio’s lack of statistical significance, the analysts were generally positive about the HARMONi findings. They highlighted how ivonescimab may perform better than Merck’s KEYTRUDA in several circumstances.
In the KEYNOTE-789 study, Ivonescimab, in combination with chemotherapy, showed a progression-free survival hazard ratio of 0.52, which was higher than KEYTRUDA’s 0.8. The analysts concluded that this comparison points to ivonescimab’s potential superiority in treating EGFRmut non-small cell lung cancer (NSCLC), which is resistant to TKIs.
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that specializes in creating novel medications for infectious and cancerous diseases.
27. Knife River Corporation (NYSE:KNF)
Analyst Upside: 49.43%
Number of Hedge Fund Holders: 28
Knife River Corporation (NYSE:KNF) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 16, RBC Capital began coverage of Knife River Corporation (NYSE:KNF) with a price target of $129 and an Outperform rating.
Knife River Corporation (NYSE:KNF) is targeting mid-sized, high-growth markets in the US, according to RBC Capital, and plans to expand its exposure to aggregates while boosting its EBITDA margin by 400 basis points, or 25%, over the medium term.
This margin gain will be accomplished through “operational efficiency improvements, pricing discipline, growth capex and M&A,” according to the firm, which also described Knife River Corporation (NYSE:KNF) as providing a “doubled-edged growth story” in terms of both revenues and margins.
RBC Capital adds that the market has not yet completely priced in the company’s EDGE strategy delivery, which presents “an attractive opportunity” for investors.
Knife River Corporation (NYSE:KNF) offers contractual services and construction supplies based on aggregates.
26. Globant S.A. (NYSE:GLOB)
Analyst Upside: 44.39%
Number of Hedge Fund Holders: 31
Globant S.A. (NYSE:GLOB) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 5, Globant S.A. (NYSE:GLOB) announced the release of its new AI Pods, a subscription-based approach for AI-powered services focusing on sectors like media, retail, and finance.
Users can sign up for a monthly subscription to the AI Pods, which operate on a token-based metered capacity. By guaranteeing time and cost savings, this strategy aims to be more in line with the results than the efforts. Co-founder and CEO of Globant Martin Migoya called the new service a “radical departure” from conventional IT offerings, highlighting its intelligent and ongoing nature.
Diego Tartara, CTO at Globant, adds that the AI Pods have already demonstrated a notable decrease in delivery schedules and an improvement in productivity in projects spanning multiple industries.
Globant S.A. (NYSE:GLOB) integrates design, technology, and innovation at scale to offer services that assist companies in their shift to digital operations. Offering a variety of services like digital marketing, automation, and artificial intelligence, the company caters to major clients like Santander, Google, and Electronic Arts.
25. Riot Platforms, Inc. (NASDAQ:RIOT)
Analyst Upside: 57.95%
Number of Hedge Fund Holders: 35
Riot Platforms Inc. (NASDAQ:RIOT) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a $15 price target, Northland analysts reiterated their Outperform rating for Riot Platforms Inc. (NASDAQ:RIOT) on June 3. This choice follows the company’s strategic appointment of Gibbs as Chief Data Center Officer.
Riot Platforms’ first-quarter 2025 call emphasized the company’s focus on building and leasing an AI/HPC data center. The company hopes to take advantage of the rising demand for hyperscaler services, which has been bolstered by robust revenue growth of 60% over the past 12 months. By hiring Gibbs, who has more than 15 years of experience in designing and constructing data centers, Riot hopes to attract top-tier tenants with advantageous lease terms.
With a pipeline of more than 1.7 GW of power close to major markets, the company is well-positioned to grow. Riot Platforms Inc. (NASDAQ:RIOT) was also expected to complete the purchase of a further 355 acres near Corsicana in May. This would enable flexible HPC architecture and may make use of all ~1 GW of available power.
Riot Platforms Inc. (NASDAQ:RIOT) is a digital infrastructure and Bitcoin mining company. In addition to electrical switchgear engineering and manufacturing facilities in Denver, it runs Bitcoin mining operations in Kentucky and central Texas.
24. PVH Corp. (NYSE:PVH)
Analyst Upside: 37.79%
Number of Hedge Fund Holders: 35
PVH Corp. (NYSE:PVH) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Jefferies analysts lowered their price target on PVH Corp. (NYSE:PVH) from $105 to $95 on June 5 while maintaining their Buy rating. The decision was made in response to the company’s most recent guidance revision.
For the most part, PVH Corp’s first-quarter earnings met expectations. Nonetheless, the company lowered its earnings per share forecast for the fiscal year 2025 by roughly 14%. The shift is a result of increased promotions, fewer choices for mitigating tariffs, and further difficulties with the Calvin Klein platform.
Sales growth for PVH Corp. (NYSE:PVH) is largely steady and suggests the brand is gaining traction. However, a potential earnings before interest and taxes inflection has been postponed due to margin constraints, and is now expected to occur in the fourth quarter.
PVH Corp. (NYSE:PVH) is a global clothing manufacturer that owns and operates a wide range of brands, including Tommy Hilfiger and Calvin Klein. Through a variety of distribution channels, the company designs, promotes, and distributes an extensive selection of clothing, accessories, and shoes.
23. QXO, Inc. (NYSE:QXO)
Analyst Upside: 58.89%
Number of Hedge Fund Holders: 36
QXO Inc. (NYSE:QXO) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 6, Wolfe Research began coverage of QXO Inc. (NYSE:QXO) with a price target of $44 and an Outperform rating. One of the main reasons for the research firm’s optimistic assessment of QXO is its potential for outstanding EBITDA growth.
Analysts at Wolfe Research praised QXO’s management team, which has a proven track record of successfully creating value across a range of industries. Through targeted mergers and acquisitions, as well as operational enhancements, the firm believes QXO Inc. (NYSE:QXO) may generate notable EBITDA growth. Wolfe also estimates that over the next five years, QXO’s EBITDA will grow at a compound annual growth rate of about 35%, considerably greater than its competitors.
QXO Inc. (NYSE:QXO) is a software company that offers Accumatica and Sage, alongside other ERP products. Additionally, it offers support, training, and other technical services associated with these products.
22. Compass, Inc. (NYSE:COMP)
Analyst Upside: 63.62%
Number of Hedge Fund Holders: 38
Compass Inc. (NYSE:COMP) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 2, UBS analysts upheld their Buy rating and kept Compass Inc. (NYSE:COMP)’s price target at $11. The update followed a recent discussion with Compass executives, including Head of Investor Relations Soham Bhonsle, CFO Kalani Reelitz, and CEO Robert Reffkin.
UBS analysts emphasized the company’s strategic focus on improving inventory depth and integrating technology with Compass’s network of more than 20,000 main agents. Despite the housing market cycle’s risks, the approach seeks to increase high-margin income streams.
The analysts also praised Compass’s efforts to increase auxiliary product attachment, grow organic agents, and maintain the growth of non-GAAP operating expenses to 3-4% annually. They also cited the company’s acquisition of reputable brokerages as an intelligent move.
Compass Inc. (NYSE:COMP) provides technology-enabled real estate brokerage services in the United States. Together with title, escrow, and home renovation finance services, it offers agents an integrated platform that includes CRM, marketing, and client support tools.
21. Churchill Downs Incorporated (NASDAQ:CHDN)
Analyst Upside: 33.19%
Number of Hedge Fund Holders: 39
Churchill Downs Incorporated (NASDAQ:CHDN) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Stifel analysts upheld their Buy rating and maintained their price target for Churchill Downs Incorporated (NASDAQ:CHDN) at $130 on June 5. The decision comes after the company’s management provided insights into their strategic outlook to investors during a series of meetings at the annual Stifel Cross Sector Insight Conference.
Churchill Downs’ management highlighted a solid setting for the 152nd Kentucky Derby and voiced confidence in the event’s pricing power throughout the meetings. Expected returns on capital expenditures and an increase in NBC media rights back this optimism.
Although there was a sequential decrease in April as a result of an adverse calendar comparison, the company expects ongoing stable growth at The Rose Dumfries. Additionally, while project specifics may be changed to account for tariff and cost concerns, management is still dedicated to the Churchill Downs Racetrack’s growth and confident in overcoming return obstacles.
Churchill Downs Incorporated (NASDAQ:CHDN) is a gambling company that offers online betting, gaming, and racing. It is divided into three business divisions: live and historical racing, wagering services, and gaming.
20. Bruker Corporation (NASDAQ:BRKR)
Analyst Upside: 37.34%
Number of Hedge Fund Holders: 40
Bruker Corporation (NASDAQ:BRKR) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, Bruker Corporation (NASDAQ:BRKR) acquired a majority investment in RECIPE, a manufacturer of diagnostic assays, marking a substantial step in the applied markets. The company also introduced the timsMetabo platform for advanced small molecule analysis.
Bruker’s therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis capabilities are improved by the investment in RECIPE. The two companies’ cooperation has resulted in the integration of Bruker’s EVOQ DART-TQ system with RECIPE’s ClinMass and ClinDART test kits. Although not yet US-FDA authorized, these kits are made to provide high-throughput, chromatography-free tests that can be utilized in laboratory-developed testing (LDT) methodologies.
Bruker Applied Mass Spectrometry Senior Vice President Jeffrey Zonderman stressed the importance of these advancements in redefining the capabilities in applied industries, particularly for environmental analysis and TDM.
Bruker Corporation (NASDAQ:BRKR), a leading American manufacturer of high-performance scientific equipment, focuses on tools for molecular and materials research, as well as industrial analysis.
19. Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Analyst Upside: 74.20%
Number of Hedge Fund Holders: 44
Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Piper Sandler analysts maintained their $148 price target for Axsome Therapeutics Inc. (NASDAQ:AXSM) and reaffirmed their Overweight rating on June 10. This decision comes after the company revealed that the FDA had sent it a Refuse to File (RTF) notice regarding its New Drug Application (NDA) for AXS-14, an oral norepinephrine reuptake inhibitor used to treat fibromyalgia.
Although Piper Sandler analysts acknowledged the setback, they stressed that Axsome’s shares are not significantly impacted by this incident. Given the lack of new agent approvals in the fibromyalgia sector over the past ten years, the analysts pointed out that the FDA’s requested additional study would be useful, and claim that Axsome Therapeutics Inc. (NASDAQ:AXSM) can support the new study with its current commercial infrastructure.
Axsome Therapeutics Inc. (NASDAQ:AXSM) is a clinical stage biopharmaceutical company that contributes to the creation of novel therapies for disorders of the central nervous system (CNS).
18. Edison International (NYSE:EIX)
Analyst Upside: 35.61%
Number of Hedge Fund Holders: 44
Edison International (NYSE:EIX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. UBS reaffirmed its Buy rating and price target of $70 for Edison International (NYSE:EIX) on June 10, as the bank views recent legislative events in California favorably.
According to UBS analyst Gregg Orrill, the California Senate passed a bill on June 4 that would enable utilities to use securitization to recover significant costs in energization and wildfire mitigation projects. The bill, SB 254, has until September 12 to be finalized and is gaining momentum.
Orrill noted that Edison International (NYSE:EIX) holds the highest rate of electric vehicle (EV) adoption in its service area, while market competitor Pacific Gas & Electric Company has the most investment in wildfire prevention among California’s investor-owned utilities.
Based in California, Edison International (NYSE:EIX) is a public utility company that specializes at generating power from a variety of sources, including renewable energy, nuclear energy, and natural gas.
17. The GEO Group, Inc. (NYSE:GEO)
Analyst Upside: 64.46%
Number of Hedge Fund Holders: 45
The GEO Group, Inc. (NYSE:GEO) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 16, the U.S. Marshals Service granted GEO Transport, a subsidiary of the The GEO Group, Inc. (NYSE:GEO), a new five-year contract for secure transportation and detention officer services.
The agreement covers 26 federal judicial districts in 14 states, with three service zones covered. According to the company’s statement, the contract is expected to earn up to $147 million over the period, or roughly $29 million in annualized revenue.
According to the company, profit margins for this contract should be comparable to those of its Managed-Only services contracts, which normally have an average of 15%. George C. Zoley, Executive Chairman of GEO, stated the following regarding the new agreement:
“This important new contract is a testament to the high-quality services GEO delivers on behalf of the U.S. Marshals Service.”
The GEO Group, Inc. (NYSE:GEO) identifies as a diversified government service provider with a focus on community reintegration centers, processing centers, and secure institutions. The company is divided into four sections: International Services, Reentry Services, Electronic Monitoring & Supervision Services, and US Secure Services.
16. Vaxcyte, Inc. (NASDAQ:PCVX)
Analyst Upside: 252.93%
Number of Hedge Fund Holders: 45
Vaxcyte Inc. (NASDAQ:PCVX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 10, Cantor Fitzgerald reiterated its Overweight rating for Vaxcyte Inc. (NASDAQ:PCVX). The update comes amid speculation regarding the potential effects on pneumococcal vaccine developers following the upcoming meeting of the Advisory Committee on Immunization Practices (ACIP).
Cantor Fitzgerald analyst Carter Gould explained the firm’s position on Vaxcyte Inc. (NASDAQ:PCVX), pointing out that the upcoming ACIP meeting is unlikely to focus much on pneumococcal disease. This implies that the meeting’s talks will have a direct impact on Vaxcyte’s operations or prospects. Gould also noted that the potential approval and ACIP recommendation of Vaxcyte’s vaccination efforts are still a few years away.
The analyst also highlighted the strength of the pneumococcal conjugate vaccine (PCV) data from Vaxcyte Inc. (NASDAQ:PCVX). Gould said that the robustness of this evidence makes a compelling case for sticking with tried-and-true vaccination practices.
A clinical-stage vaccine pioneer, Vaxcyte, Inc. (NASDAQ:PCVX) develops, refines, and produces high-fidelity vaccines. The company’s medications aim to prevent or cure bacterial illnesses such as Shigella, Group A Strep, invasive pneumococcal disease, and periodontitis.
15. Remitly Global, Inc. (NASDAQ:RELY)
Analyst Upside: 40.43%
Number of Hedge Fund Holders: 46
Remitly Global Inc. (NASDAQ:RELY) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 5, analysts at BMO Capital maintained their price target of $30 and reaffirmed their Outperform rating for Remitly Global Inc. (NASDAQ:RELY). The analysts pointed to Wise’s intention to relocate its primary listing from London to the United States as a possible boost for Remitly, stating that even if Remitly’s growth is faster than Wise’s, its shares are now trading at a substantial discount to its competitor.
Wise’s entry into the US market is not seen by analysts as posing a medium-term threat to Remitly Global Inc. (NASDAQ:RELY). They underlined that Wise and Remitly serve a very different customer base, suggesting that the competitive environment would be steady for the foreseeable future.
The planned U.S. remittance tax, however, continues to raise concerns and has an impact on Remitly’s shares. Although the analysts acknowledged this uncertainty, they noted that if the tax is eliminated or decreased, the stock might rise again.
A leading supplier of cross-border digital financial services, Remitly Global Inc. (NASDAQ:RELY) focuses on online remittance solutions. The company offers quick and easy international money transfers to more than 170 nations.
14. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Analyst Upside: 47.34%
Number of Hedge Fund Holders: 46
Madrigal Pharmaceuticals (NASDAQ:MDGL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With a price target of $470, Citizens JMP analysts reiterated their Market Outperform rating for Madrigal Pharmaceuticals (NASDAQ:MDGL) on June 5. The analysts discussed future developments that would affect the company’s prospects.
On June 7, Madrigal Pharmaceuticals was scheduled to hold a product theater called “Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra.” It was expected that this event would offer insight into the early experiences of the endocrinology community with Rezdiffra, the first medication for MASH.
The analysts were focused on doctors recognizing MASH in their diabetic patients and what treatment plans they apply as a result. With analysts predicting strong sales growth for the current year, these insights might significantly increase Rezdiffra’s market potential.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company committed to developing novel treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition with an unmet medical need.
13. Burlington Stores, Inc. (NYSE:BURL)
Analyst Upside: 37.81%
Number of Hedge Fund Holders: 48
Burlington Stores Inc. (NYSE:BURL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. UBS analysts maintained their $390 price target for Burlington Stores Inc. (NYSE:BURL) and reaffirmed their Buy rating on the company’s shares on June 2.
As per UBS, Burlington’s “Burlington 2.0” approach is working well. Burlington Stores Inc. (NYSE:BURL) is anticipated to stand out from other Softline stocks this year that lack comparable initiatives by continuing to offer substantial margin improvements.
UBS analysts also emphasized how tariffs could help Burlington Stores Inc. (NYSE:BURL) . As tariffs affect department stores, they expect a shift in market share towards off-price retailers, such as Burlington. Additionally, they add that Burlington Stores should eventually profit from the inventory issues that the tariffs would cause in the retail industry.
Burlington Stores, Inc. (NYSE:BURL) is a discount retailer of branded clothing. Additionally, it offers comparatively cheaper household goods, footwear, and accessories. The company runs over 1007 locations, mostly under the Burlington Stores brand.
12. Wix.com Ltd. (NASDAQ:WIX)
Analyst Upside: 39.84%
Number of Hedge Fund Holders: 50
Wix.com Ltd. (NASDAQ:WIX) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 18, Barclays maintained its $240 price target and Overweight rating on Wix.com Ltd. (NASDAQ:WIX).
The rating confirmation comes after Wix.com Ltd. (NASDAQ:WIX) recently announced that it had acquired “Hour One,” a company with generative AI capabilities, just weeks prior.
Wix’s business strategy may be changing, according to Barclays, which said, “We do wonder if Wix is beginning to prioritize M&A as a larger part of its capital allocation strategy.” That said, Barclays does not see Wix pursuing significant game-changing acquisitions, despite the recent deals. The firm stated that smaller purchases could yet occur while large-scale M&A seems unlikely.
In particular, the research firm stated that it “would not be surprised to see more of these tuck-in deals to bolster talent/product capabilities,” implying that Wix.com Ltd. (NASDAQ:WIX) would keep making targeted acquisitions to improve its current technological expertise and service offerings.
Wix.com Ltd. (NASDAQ:WIX) is a cloud-based platform that enables those without technical expertise to create websites. It offers Wix Editor, Wix ADI, and numerous other services.
11. First Solar, Inc. (NASDAQ:FSLR)
Analyst Upside: 46.02%
Number of Hedge Fund Holders: 52
First Solar Inc. (NASDAQ:FSLR) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 11, Jefferies raised its price target for First Solar Inc. (NASDAQ:FSLR) from $175 to $192, upgrading the company to Buy on the basis of improved pricing power and more definite legislative support for U.S.-based solar manufacturers.
Tighter regulations on Chinese-affiliated suppliers, according to Jefferies, are probably going to reduce competitiveness and increase demand for First Solar, Inc. (NASDAQ:FSLR)’s domestically manufactured modules. The firm anticipates a significant increase in average selling prices for solar modules, particularly if current contract pricing shifts toward 32–33 cents per watt.
As regulatory certainty improves in the upcoming weeks, Jefferies dubbed First Solar’s stock as “compelling” and pointed out that the company is trading at a substantial discount to rivals despite generating faster profit growth.
First Solar, Inc. (NASDAQ:FSLR) is an American solar technology company and a global supplier of sustainably produced eco-efficient solar modules.
10. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Analyst Upside: 68.82%
Number of Hedge Fund Holders: 52
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, UBS reiterated its Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ), citing a $164 price target. The update followed a group KOL dinner and speeches at the ASCO 2025 conference, which bolstered their optimism about the company’s future.
Positive results from a Phase 2 trial that combined zani with chemotherapy for GEA were highlighted by the analysts. The trial’s confirmed objective response rate (cORR) was 83.8% for patients with centrally confirmed HER2+ GEA and 76.2% for all participants. The trial also found that the median overall survival was 36.5 months.
Additionally, UBS analysts spoke with ZYME, a partner of Jazz Pharmaceuticals plc (NASDAQ:JAZZ), on the data read-out schedule. The results of the study were greeted with optimism when management expressed confidence that the data would be accessible by the third quarter of 2025.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.
9. GitLab Inc. (NASDAQ:GTLB)
Analyst Upside: 49.45%
Number of Hedge Fund Holders: 52
GitLab Inc. (NASDAQ:GTLB) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 11, Canaccord Genuity maintained its Buy rating on GitLab Inc. (NASDAQ:GTLB), while decreasing its price target to $76 from $78.
Canaccord stressed that despite the current software purchasing climate, GitLab Inc. (NASDAQ:GTLB) continues to show robust revenue growth from seat expansions, which the firm sees as proof that the platform’s value proposition appeals to users.
The research firm highlighted GitLab’s distinctive end-to-end platform approach, which starts with source code management, and pointed out that IT buyers continue to place a high premium on investing in the software supply chain.
Canaccord also mentioned GitLab’s success in turning a profit, stating that it expects operating leverage to develop organically as the company scales into what it refers to as a sizable software deployment market.
GitLab Inc. (NASDAQ:GTLB) offers a uniform platform that supports the full software development lifecycle, enabling teams to design, create, protect, and launch applications across various cloud environments.
8. Bill.com Holdings, Inc. (NYSE:BILL)
Analyst Upside: 36.30%
Number of Hedge Fund Holders: 53
Bill.com Holdings, Inc. (NYSE:BILL) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Bill.com Holdings, Inc. (NYSE:BILL) was lowered from an Overweight to Equalweight by Morgan Stanley analysts on June 11. The firm also lowered the company’s price target from $60 to $55.
The analysts referenced a reexamination of their earlier thesis, which centered on stronger monetization strategies, an undemanding valuation, and improving expenditure trends for small and medium-sized businesses (SMBs). They observed a short-term decline in optimism regarding each of these elements.
That said, analysts at Morgan Stanley indicated that Bill.com Holdings, Inc. (NYSE:BILL) had an optimistic future despite the downgrade. They believe the company’s software platform, which is underappreciated by investors, can grow and generate greater revenue.
Bill.com Holdings, Inc. (NYSE:BILL) is a financial operations platform that caters to small and midsize businesses (SMBs). The company enables SMBs manage their accounts by offering a suite of software products, including BILL Platform, Divvy, Invoice2go, and BILL Pay.
7. Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Analyst Upside: 73.45%
Number of Hedge Fund Holders: 54
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. RBC Capital maintained its Outperform rating on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and increased its price target from $55 to $57 on June 13. The change comes after the company examined the translatability of previous Phase II to Phase III medications for epilepsy.
The bank’s study showed a strong association between the efficacy results of Phase II and Phase III drugs for focal onset seizures, particularly in terms of responder rates and seizure reductions. According to the findings, Xenon’s top medication candidate, azetukalner, will likely exhibit similarly encouraging outcomes in its Phase III data, which is expected to be released early next year.
Azetukalner’s novel Kv7 mechanism of action, quick onset, and possible mood improvements are cited by RBC Capital as competitive advantages in a market dominated by polypharmacy, with the firm suggesting that future sales might reach $1.2 billion.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a biopharmaceutical company that specializes in creating therapies for mental and neurological conditions, such as major depressive disorder (MDD) and epilepsy.
6. Revolution Medicines, Inc. (NASDAQ:RVMD)
Analyst Upside: 76.88%
Number of Hedge Fund Holders: 61
Revolution Medicines, Inc. (NASDAQ:RVMD) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Oppenheimer analysts maintained their $75 price target for Revolution Medicines, Inc. (NASDAQ:RVMD) and reaffirmed their Outperform rating on June 3. Updates from competing KRAS initiatives that were given at this year’s ASCO meeting coincide with the reaffirmation.
The Oppenheimer analysts pointed out that smaller datasets would provide difficulties for Revolution’s rivals in the G12Di arena for pancreatic ductal adenocarcinoma (PDAC). That said, Revolution’s Phase 3 trials in second-line and beyond are currently recruiting for PDAC and non-small cell lung cancer (NSCLC.
With the initiation of registrational trials in the adjuvant context and first-line metastatic PDAC, focus is now turning to front-line prospects. Potential pipeline updates that could further inform Revolution’s development plan are anticipated by the analysts for the second half of the year.
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage biotech company that develops cancer medications that target RAS, a major category of genetic abnormalities that are frequently present in difficult-to-treat cancers.
5. Primo Brands Corporation (NYSE:PRMB)
Analyst Upside: 41.85%
Number of Hedge Fund Holders: 66
Primo Brands Corporation (NYSE:PRMB) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. With an Overweight rating and a $40 price target, Barclays analysts began covering Primo Brands Corporation (NYSE:PRMB). Primo Brands was cited by the analysts as an interesting consolidation story in the food and beverage industry, owing to its ability to withstand several structural issues that other companies in the sector face.
The analysts cited the BlueTriton and legacy Primo combination as a major contributor to the development of a varied portfolio of market channels, formats, and brands. In the upcoming years, this merger is expected to offer a strong basis for consistent top-line growth of 3-5%.
Analysts at Barclays also highlighted the possibility of a high single-digit compound annual growth rate for adjusted EBITDA between 2025 and 2027. Primo Brands Corporation (NYSE:PRMB) is expected to keep implementing its synergy program, which is likely to improve the company’s financial performance, leading to this growth.
Primo Brands Corporation (NYSE:PRMB) is a North American beverage company that specializes in optimal hydration. The company supplies an array of branded beverages at 200,000 retail outlets.
4. SharkNinja, Inc. (NYSE:SN)
Analyst Upside: 36.68%
Number of Hedge Fund Holders: 69
SharkNinja, Inc. (NYSE:SN) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 3, William Blair reiterated its Outperform rating for SharkNinja, Inc. (NYSE:SN). The update was made amid persistent issues with inventory shortages and tariffs, which are anticipated to affect the company’s performance in the second quarter.
According to the firm, customer demand is still steady, but the supply of key products—especially those sold under the Ninja brand—is being impacted by the brief suspension of orders from China. That said, SharkNinja Inc. (NYSE:SN) believes it can still reach its sales growth target of 9.5% for the quarter despite these obstacles.
In addition to contemplating domestic manufacture for some products, SharkNinja Inc. (NYSE:SN) is actively expanding its supply chain. To maintain inventories, the company has also hiked prices on roughly 32% of its product line since mid-April, which might have an impact on short-term demand. Despite these obstacles, SharkNinja Inc. (NYSE:SN) hopes to potentially accelerate its gains in market share later in the year as inventory levels level out.
SharkNinja Inc. (NYSE:SN) is a technology and product design company that operates under the Shark and Ninja brands. It provides consumer solutions for home appliances, cleaning, cooking, food preparation, and cosmetics.
3. DraftKings Inc. (NASDAQ:DKNG)
Analyst Upside: 43.29%
Number of Hedge Fund Holders: 70
DraftKings Inc. (NASDAQ:DKNG) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. An Outperform rating on DraftKings Inc. (NASDAQ:DKNG) with a price target of $46 was reaffirmed by Bernstein SocGen Group on June 16. The firm noted what it calls the company’s “compelling and differentiated investment case” in the context of online sports betting and iGaming.
One of DraftKings’ primary advantages, according to the firm, is its improved live pricing capabilities, which were “significantly boosted by the SimpleBet acquisition.” These capabilities, according to Bernstein, enable the company to capture significant growth in the US live betting market while delivering strong handle and profitability growth.
Additionally, the company found unrealized potential in cross-selling Jackpocket to live betting clients. One major looming driver for DraftKings Inc. (NASDAQ:DKNG) was the incorporation of Jackpocket into the company’s core platform. Bernstein’s optimistic assessment of DraftKings remains focused on user profitability, as the firm projects average revenue per user growth in the mid-single digits.
DraftKings Inc. (NASDAQ:DKNG) is a digital sports entertainment and gaming company that offers sports betting, digital lottery courier, daily fantasy sports, and other products. Additionally, it offers online casino games, including roulette, slot machines, blackjack, and baccarat.
2. MongoDB, Inc. (NASDAQ:MDB)
Analyst Upside: 31.20%
Number of Hedge Fund Holders: 72
MongoDB, Inc. (NASDAQ:MDB) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. On June 9, Cantor Fitzgerald retained its Overweight rating on MongoDB, Inc. (NASDAQ:MDB), alongside a $271 price target on the company’s shares. MongoDB’s strong start to fiscal year 2026 was emphasized by the firm’s analysts, who highlighted a notable rebound in May and June after a decline in April.
Management at MongoDB, Inc. (NASDAQ:MDB) remains optimistic about Atlas’ potential for growth of more than 20%, even when enterprise agreements are expected to drop by a high single-digit percentage for the rest of the fiscal year.
Discussions with the CFO of MongoDB, Inc. (NASDAQ:MDB) revealed that Atlas usage had resumed its previous trends. This comeback is viewed as encouraging for the company’s future growth. Moreover, according to Cantor Fitzgerald analysts, MongoDB’s reference to a well-known AI client utilizing its platform alleviated worries regarding the company’s strategic placement within the enterprise AI data stack.
MongoDB, Inc. (NASDAQ:MDB) offers a versatile database platform that includes enterprise-grade solutions, cloud-based services, and a free version for developers.
1. Alibaba Group Holding Limited (NYSE:BABA)
Analyst Upside: 46.27%
Number of Hedge Fund Holders: 125
Alibaba Group Holding Limited (NYSE: BABA) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. In order to enhance its regional infrastructure and satisfy the growing demand for AI and cloud services, Alibaba Cloud, the cloud computing division of Alibaba Group Holding Limited (NYSE: BABA), announced plans to open a second data center in South Korea on June 18.
In addition to the company’s current Korean node, which was inaugurated in 2022, the new facility will be situated close to Seoul and will enhance computing capacity and redundancy for enterprise and government clients.
This comes at a time when Alibaba Cloud is investing more than $52 billion in AI-driven infrastructure across Asia, Europe, the Americas, and the Middle East as part of its “unified global cloud network.”
Alibaba Group Holding Limited (NYSE: BABA) is an e-commerce and technology company that caters to small business owners and consumers. The company is also a pioneer in cloud computing, logistics, and digital media.
While we acknowledge the potential of BABA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BABA and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None.
